These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 20662558)
1. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. Wierzbicki AS; Morrell J; Hemsley D; McMahon Z; Crook MA; Wray R Curr Med Res Opin; 2010 Sep; 26(9):2141-6. PubMed ID: 20662558 [TBL] [Abstract][Full Text] [Related]
2. Statin-fibrate combination for mixed dyslipidaemia: a limited option? Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP Curr Med Res Opin; 2010 Sep; 26(9):2137-40. PubMed ID: 20662560 [TBL] [Abstract][Full Text] [Related]
3. [Part II. Combination statin plus fibrate regimens (free and fixed)]. Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():11-9. PubMed ID: 27473466 [No Abstract] [Full Text] [Related]
4. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions. Alford JC; Saseen JJ; Allen RR; Nair KV Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173 [TBL] [Abstract][Full Text] [Related]
5. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents]. Soska V Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414 [TBL] [Abstract][Full Text] [Related]
6. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557 [TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Suh HS; Hay JW; Johnson KA; Doctor JN Pharmacoepidemiol Drug Saf; 2012 May; 21(5):470-84. PubMed ID: 22461130 [TBL] [Abstract][Full Text] [Related]
8. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360 [TBL] [Abstract][Full Text] [Related]
10. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis. Choi HD; Shin WG; Lee JY; Kang BC Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563 [TBL] [Abstract][Full Text] [Related]
12. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe? Milionis H Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564 [TBL] [Abstract][Full Text] [Related]
13. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?]. Pérez A Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585 [No Abstract] [Full Text] [Related]
14. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Mohiuddin SM; Thakker KM; Setze CM; Kelly MT Curr Med Res Opin; 2011 May; 27(5):1067-78. PubMed ID: 21438793 [TBL] [Abstract][Full Text] [Related]
15. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645 [TBL] [Abstract][Full Text] [Related]
17. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Corrao G; Conti V; Merlino L; Catapano AL; Mancia G Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788 [TBL] [Abstract][Full Text] [Related]
18. Fibrates: where are we now? Seth Loomba R; Arora R Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M; Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022 [TBL] [Abstract][Full Text] [Related]
20. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Heintjes EM; Penning-van Beest FJ; Johansson S; Stalenhoef AF; Herings RM Curr Med Res Opin; 2009 Nov; 25(11):2621-9. PubMed ID: 19743959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]